Search Results - "Hernberg, M"

BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis by Ny, L, Hernberg, M, Nyakas, M, Koivunen, J, Oddershede, L, Yoon, M, Wang, X, Guyot, P, Geisler, J

“…The analysis of the BRAF mutational status has been established as a standard procedure during diagnosis of advanced malignant melanoma due to the fact that…”
Get more information

Increased incidence of melanoma in children and adolescents in Finland in 1990-2014: nationwide re-evaluation of histopathological characteristics by Rousi, Emma K., Kallionpää, Roope A., Kallionpää, Roosa E., Juteau, Susanna M., Talve, Lauri A. I., Hernberg, Micaela M., Vihinen, Pia P., Kähäri, Veli-Matti, Koskivuo, Ilkka O.

“…Changes in the incidence of melanoma in children and adolescents have been reported in Europe and in the USA in the recent decades. The aim of this study was…”
Get full text

SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY by Østenstad, B., Pirosa, M. C., Schär, S., Brodtkorb, M., Wahlin, B. E., Hernberg, M., Pedersen, M., Stathis, A., Zander, T., Novak, U., Zenz, T., Fischer, N., Krasniqi, F., Hitz, F., Jjohansson, A., Lofgren, D., Meyer, P., Bjørnevik, A. T., Hayoz, S., Scheibe, B., Steiner, L., Dirnhofer, S., Ceriani, L., Zucca, E.

Get full text

Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma by Lundberg, M, Haapaniemi, A, Hagstrom, J, Juteau, S, Hernberg, M, Makitie, A A, Vento, S I

“…To describe a cohort of sinonasal mucosal melanoma (SNMM) patients, and to assess if choice of surgical approach (open versus endoscopic) has impact on…”
Get full text

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b by Brandberg, Y, Aamdal, S, Bastholt, L, Hernberg, M, Stierner, U, von der Maase, H, Hansson, J

“…Abstract Purpose To compare health-related quality of life (HRQoL) and side-effects in patients with high-risk melanoma participating in a randomised phase III…”
Get full text

PROGNOSTIC IMPLICATIONS OF THE MICROENVIRONMENT IN FOLLICULAR LYMPHOMA UNDER RITUXIMAB AND RITUXIMAB+LENALIDOMIDE THERAPY. A TRANSLATIONAL STUDY OF THE SAKK35/10 TRIAL by Menter, T., Tzankov, A., Zucca, E., Kimby, E., Vanazzi, A., Østenstad, B., Mey, U.J., Rauch, D., Wahlin, B., Hitz, F., Hernberg, M., Johansson, A., Nully Brown, P., Hagberg, H., Hawle, H., Hayoz, S., Dirnhofer, S.

Get full text

Metastatic uveal melanoma: The final frontier by Rantala, Elina S., Hernberg, Micaela M., Piperno-Neumann, Sophie, Grossniklaus, Hans E., Kivelä, Tero T.

“…Treatment of primary intraocular uveal melanoma has developed considerably, its driver genes are largely unraveled, and the ways to assess its risk for…”
Get full text

Nivolumab in Previously Untreated Melanoma without BRAF Mutation by Robert, Caroline, Long, Georgina V, Brady, Benjamin, Dutriaux, Caroline, Maio, Michele, Mortier, Laurent, Hassel, Jessica C, Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J, Hernberg, Micaela M, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Arance, Ana, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Eriksson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian M, Atkinson, Victoria, Ascierto, Paolo A

“…In this trial, the anti–programmed death 1 antibody nivolumab was associated with a significantly higher response rate and longer survival than standard…”
Get full text

Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma by Koskivuo, I., Hernberg, M., Vihinen, P., Virolainen, S., Talve, L., Seppänen, M., Vahlberg, T., Jahkola, T.

“…Background: Sentinel lymph node biopsy (SNB) is a widely adopted staging procedure in patients with cutaneous melanoma. The benefits of SNB have not been…”
Get full text

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma by Robert, Caroline, Long, Georgina V, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Rutkowski, Piotr, Hassel, Jessica C, McNeil, Catriona M, Kalinka, Ewa Anna, Lebbé, Céleste, Charles, Julie, Hernberg, Micaela M, Savage, Kerry J, Chiarion-Sileni, Vanna, Mihalcioiu, Catalin, Mauch, Cornelia, Arance, Ana, Cognetti, Francesco, Ny, Lars, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Zoco, Jesús, Re, Sandra, Ascierto, Paolo A, Atkinson, Victoria

“…The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated wild-type advanced melanoma…”
Get full text

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial by Ascierto, Paolo A, Long, Georgina V, Robert, Caroline, Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Hassel, Jessica C, Rutkowski, Piotr, McNeil, Catriona, Kalinka-Warzocha, Ewa, Savage, Kerry J, Hernberg, Micaela M, Lebbé, Celeste, Charles, Julie, Mihalcioiu, Catalin, Chiarion-Sileni, Vanna, Mauch, Cornelia, Cognetti, Francesco, Ny, Lars, Arance, Ana, Svane, Inge Marie, Schadendorf, Dirk, Gogas, Helen, Saci, Abdel, Jiang, Joel, Rizzo, Jasmine, Atkinson, Victoria

“…This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1…”
Get more information

Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma by Hansson, J., Aamdal, S., Bastholt, L., Hernberg, M., Nilsson, B., Stierner, U. K., von der Maase, H., Brandberg, Y.

“…Abstract only…”
Get full text

Determinants of Long-Term Survival in Metastatic Choroidal and Ciliary Body Melanoma by Rantala, Elina S., Parrozzani, Raffaele, Hernberg, Micaela M., Chiarion-Sileni, Vanna, Kivelä, Tero T., Midena, Edoardo

“…To build and validate a prognostic model that predicts long-term overall survival (OS) in metastatic choroidal and ciliary body melanoma (CCBM) to facilitate…”
Get full text

Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma by HERNBERG, Micaela, VIRKKUNEN, Pekka, BONO, Petri, AHTINEN, Henna, MÄENPÄÄ, Hanna, JOENSUU, Heikki

“…The antiangiogenic effect of interferon (IFN) may improve with frequent dosing and by combination with other agents with antiangiogenic activity. To evaluate…”
Get full text

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial by Hansson, Johan, Dr, Aamdal, Steinar, Prof, Bastholt, Lars, MD, Brandberg, Yvonne, Prof, Hernberg, Micaela, MD, Nilsson, Bo, MSc, Stierner, Ulrika, MD, von der Maase, Hans, Prof

“…Summary Background Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall…”
Get full text

Impact of staging on survival outcomes: a nationwide real-world cohort study of metastatic uveal melanoma by Rantala, Elina S., Kivelä, Tero T., Hernberg, Micaela M.

“…No data exist regarding whether any first-line treatment for metastatic uveal melanoma provides overall survival (OS) benefit, if staged and compared to best…”
Get full text

Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014 by Rousi, Emma K, Koskivuo, Ilkka O, Juteau, Susanna M, Talve, Lauri A I, Hernberg, Micaela M, Vihinen, Pia P, Kähäri, Veli-Matti

“…Pediatric melanoma may have a different biological background and more favorable prognosis compared with melanoma in adults. The aim of this study was to…”
Get more information

Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007–2018 by Tulokas, Sanni K. A., Kohtamäki, Laura M., Mäkelä, Siru P., Juteau, Susanna, Albäck, Anders, Vikatmaa, Pirkka J., Mattila, Kalle E., Skyttä, Tanja K., Koivunen, Jussi P., Tyynelä-Korhonen, Kristiina, Hernberg, Micaela M.

“…Isolated limb perfusion (ILP) is widely accepted as treatment for recurrent melanoma limited to the limbs. The use of ILP has decreased in recent years with…”
Get full text

PO-1554 Degraded 4 MeV electron beam in treating basal cell carcinoma: Safety study by Valve, A., Koskenmies, S., Anttonen, A., Nurmi, H., Hernberg, M., Tenhunen, M.

Get full text

The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma by Hernberg, Micaela M, Hahka-Kemppinen, Marjo H, Pyrhönen, Seppo O

“…We have observed that an early increase in the CD4+/CD8+ ratio of metastatic melanoma patients during chemoimmunotherapy is the most favourable independent…”
Get full text